A recent study of 24 patients with HIV-associated TTP emphasises the importance of the prompt initiation/re-initiation of cART in parallel with plasma exchange and steroid treatment that lead to prompt remission. 10 Adjunct immunomodulatory agents such as rituximab have been used with some success in refractory cases. 10 It has been reported that patients with HIV-associated TTP seem to be far more responsive to plasma infusion treatment regimens than their HIV-negative counterparts, suggesting a different pathophysiology.
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Pathophysiology of HIV-associated Thrombotic Thrombocytopenic Purpura
The pathophysiology and initial onset of TTP in HIV-positive patients are not fully understood. HIV-positive persons visiting the local primary healthcare clinic. The control HIV group was divided into two groups, depending on whether they were on cART or not. The ADAMTS13 levels and autoantibodies were measured using the respective enzyme-linked immunosorbent assay (ELISA) kits from American Diagnostica (US).
The ADAMTS13 activities were measured using the Actifluor™ ADAMTS13 fluorescence resonance energy transfer (FRET) assay (also from American Diagnostica). We also measured the VWF levels using antibodies from Dako (South Africa) and tissue factor levels in plasma with an ELISA kit from American Diagnostica. The results are summarised in Table 1 .
We found that the ADAMTS13 levels extensively decreased in TTP patients. HIV infection on its own did not seem to have a significant influence on ADAMTS13 levels. However, HIV-positive persons who
were not on cART seemed to have slightly lower ADAMTS13 levels than those who were on cART, although the levels were still in the normal range. It is possible that less metalloproteases such as ADAMTS13
are synthesised in these patients, since micronutrient deficiencies are widespread and compound the effects of HIV disease. 16 Our findings regarding ADAMTS13 levels differed from those of another group in South Africa. They detect normal ADAMTS13 levels in one-third of adult cases with HIV-associated TTP. 8 The activities of ADAMTS13 that we measured using the FRET assay did not correlate with the ADAMTS13 levels in all groups. However, the lowest activities were found in the TTP patients. The assay might not be as suitable as the ADAMTS13 levels to diagnose the presence of HIV-associated TTP. We also found that only 50 % of our TTP patients presented with autoantibodies to ADAMTS13.
This correlates with what is reported in the literature. 14 An interesting finding was that most of the HIV-positive persons who were not on cART also presented with high amounts of autoantibodies against ADAMTS13. We thus suggest that antibody formation against ADAMTS13 is a result of the weakened immune system in HIV.
Similar to what is reported in the literature, we found increased VWF levels in patients with HIV-associated TTP. 8 The VWF antigen levels were greatly increased in HIV-positive patients who were not on cART. This could be due to an HIV-associated inflammatory state or concomitant infection. Similar to the VWF levels, we found that most (87 %) of the HIV-positive persons who were not on cART had increased tissue factor levels, which is known to be a risk factor for thrombosis. We found that only 36 % of the TTP patients presented with increased tissue factor levels. This is probably because these patients were all on cART.
We propose a mechanism for the initial onset of HIV-associated TTP (see Figure 1) . HIV type 1 (HIV-1) infection is associated with inflammation and elevated levels of inflammatory cytokines such as gamma interferon and tumour necrosis factor alpha (TNF-α) and beta (TNF-β). 17 It is known that inflammatory cytokines, such as TNF-α and interleukin-1, 6 and 8, have profound stimulatory effects on the endothelial release of ULVWF 18 In addition, the synthesis of ADAMTS13 that cleaves the ULVWF is inhibited. 19 This might ultimately lead to the deficiency of ADAMTS-13 and the overexpression of ULVWF, resulting in the initiation of TTP. Furthermore, HIV-infection is associated with widespread micronutrient deficiencies that might cause decreased ADAMTS13 synthesis. 16 Autoantibodies to ADAMTS13 are also present in HIV-positive patients as a result of the weakened immune system. An inhibitory antibody might also cause the initial onset of HIV-associated TTP.
Laboratory Diagnosis of HIV-associated Thrombotic Thrombocytopenic Purpura
The diagnosis of TTP rests on evidence of microangiopathic 20 We suggest the use of ADAMTS13 levels as a confirmatory test of HIV-associated TTP. The measurement of ADAMTS13 activity levels using the FRET assay is expensive and does not necessarily confirm the disease. The exact role of inhibitory autoantibodies to ADAMTS13 remains uncertain and further investigation is required.
Conclusion
HIV-associated TTP is a heterogeneous disorder and its initial onset is still not clear. We propose that infection with HIV might trigger the disease through the inflammatory process. Inflammatory cytokines stimulate the release of extreme amounts of VWF. 17 Extremely high levels of VWF were found in the plasma of HIV-positive persons who are not on HAART as well as in TTP plasma. The cytokines also downregulate the release of the VWF-cleaving protease ADAMTS13. 19 We found very low levels of ADAMTS13 in TTP plasma. This might be sufficient to cause thrombotic microangiopathy and precipitate an acute episode of TTP even in the presence of normal cleaving protease activity. Furthermore, the release of VWF may be sufficient to overwhelm the capacity of the cleaving protease and result in a 'consumptive deficiency', as speculated by Gunther et al. 14 
